- Home
- TCPC vs REPL Comparison
TCPC vs REPL Comparison
Compare TCPC & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCPC
- REPL
- Stock Information
- Founded
- TCPC 2006
- REPL 2015
- Country
- TCPC United States
- REPL United States
- Employees
- TCPC N/A
- REPL N/A
- Industry
- TCPC Finance/Investors Services
- REPL Biotechnology: Pharmaceutical Preparations
- Sector
- TCPC Finance
- REPL Health Care
- Exchange
- TCPC Nasdaq
- REPL Nasdaq
- Market Cap
- TCPC 603.8M
- REPL 547.0M
- IPO Year
- TCPC 2012
- REPL 2018
- Fundamental
- Price
- TCPC $7.16
- REPL $5.40
- Analyst Decision
- TCPC Sell
- REPL Buy
- Analyst Count
- TCPC 2
- REPL 10
- Target Price
- TCPC $6.75
- REPL $8.25
- AVG Volume (30 Days)
- TCPC 523.9K
- REPL 4.5M
- Earning Date
- TCPC 08-07-2025
- REPL 08-07-2025
- Dividend Yield
- TCPC 16.92%
- REPL N/A
- EPS Growth
- TCPC N/A
- REPL N/A
- EPS
- TCPC N/A
- REPL N/A
- Revenue
- TCPC $239,535,768.00
- REPL N/A
- Revenue This Year
- TCPC N/A
- REPL N/A
- Revenue Next Year
- TCPC N/A
- REPL $408.25
- P/E Ratio
- TCPC N/A
- REPL N/A
- Revenue Growth
- TCPC 3.11
- REPL N/A
- 52 Week Low
- TCPC $6.27
- REPL $2.68
- 52 Week High
- TCPC $9.72
- REPL $17.00
- Technical
- Relative Strength Index (RSI)
- TCPC 46.41
- REPL 44.04
- Support Level
- TCPC $7.02
- REPL $5.08
- Resistance Level
- TCPC $7.17
- REPL $5.91
- Average True Range (ATR)
- TCPC 0.12
- REPL 0.33
- MACD
- TCPC 0.02
- REPL 0.15
- Stochastic Oscillator
- TCPC 66.67
- REPL 46.88
About TCPC BlackRock TCP Capital Corp.
BlackRock TCP Capital Corp is an externally-managed specialty finance company focused on middle-market lending. Its investment objective is to achieve high total returns through current income and capital appreciation, with an emphasis on principal protection. It seeks to achieve investment objective through investments in debt securities of middle-market companies. The group generates returns through a combination of the receipt of contractual interest payments on debt investments and origination and similar fees, and, to a lesser extent, equity appreciation through options, warrants, conversion rights or direct equity investments.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.